Sanofi mulls Lyxumia lixisenatide market positioning with ADA data
This article was originally published in Scrip
Executive Summary
Data unveiled at the American Diabetes Association (ADA) 71st scientific sessions suggests that while Lyxumia (lixisenatide), from Sanofi, dosed once daily had met its endpoint of non-inferiority to Byetta (exenatide) in the treatment of Type 2 diabetes, the real battle will be to take on Victoza, (liraglutide), the once daily injectable GLP-1 analogue from Novo Nordisk. Moreover, it is likely that Sanofi will not pursue obesity as a target indication for lixisenatide.